Loading...
The development of therapeutic monoclonal antibodies for myeloma has lagged well behind such advances in treating non-Hodgkin lymphoma. Now, investigators have conducted an industry-sponsored, randomized, phase III trial to test the potential benefit of adding the monoclonal antibody elotuzumab to standard therapy (lenalidomide plus dexamethasone) versus standard therapy alone in 646 patients with relapsed or refractory myeloma who had received a median of two prior treatments. Of these patients, 35% were resistant to their most recent regimen, and 32% had poor-risk cytogenetics, including del(17p).
At a median follow-up of 24.5 months, the overall response rate was improved with the elotuzumab regimen versus standard therapy (79% vs. 66%; P…